George Bright
Adolescent Medicine · Midlothian, VANPI 1235181702
Payments from drug & device makers
Across 1,163 payments — averaging $244.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Ironshore Pharmaceuticals Inc.$141K
- Neos Therapeutics, LP$77K
- Tris Pharma Inc$22K
- Corium, LLC$22K
- Aytu Biopharma, Inc.$14K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2K
- plus $7K from 21 others
What the payments were for
- Consulting fees$31,34511%
- Speaking & faculty fees$209,36674%
- Travel & lodging$23,6618%
- Food & beverage$19,5527%
- Education$630%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Ironshore Pharmaceuticals Inc. | 313 | $140,973 |
| Neos Therapeutics, LP | 255 | $77,366 |
| Tris Pharma Inc | 92 | $21,963 |
| Corium, LLC | 133 | $21,949 |
| Aytu Biopharma, Inc. | 39 | $13,666 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 83 | $1,547 |
| Otsuka America Pharmaceutical, Inc. | 39 | $1,205 |
| Eton Pharmaceuticals, Inc. | 1 | $1,000 |
| MDD US Operations, LLC | 5 | $587 |
| Neurocrine Biosciences, Inc. | 25 | $570 |
| Lundbeck LLC | 35 | $523 |
| Takeda Pharmaceuticals U.S.A., Inc. | 26 | $468 |
| Axsome Therapeutics, Inc. | 13 | $409 |
| Supernus Pharmaceuticals, Inc. | 20 | $322 |
| AbbVie | 15 | $240 |
| Almatica Pharma LLC | 11 | $236 |
| Eisai Inc. | 17 | $190 |
| Orexo US, Inc. | 9 | $181 |
| Idorsia Pharmaceuticals US Inc | 7 | $175 |
| Collegium Pharmaceutical, Inc. | 10 | $153 |
| Indivior Inc. | 5 | $108 |
| Merck | 4 | $57 |
| Alkermes, Inc. | 2 | $39 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $15 |
| Shire North American Group Inc | 1 | $15 |
| Kaleo, Inc. | 1 | $15 |
| Johnson & Johnson | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JORNAY PM$73,282
- Adzenys XR-ODT$65,399
- Jornay PM 20mg capsules (Bottle of 100)$64,001
- Cotempla XR-ODT$59,772
- Azstarys$20,482
- ZolpiMist$11,118
- Dyanavel XR$9,874
- Quillivant$6,525
- Quillichew ER$6,525
- Onyda XR$5,600
- Alkindi$1,000
- KHINDIVI$1,000
- INCRELEX$1,000
- CAPLYTA$633
- Lucemyra/Lofexidine$500
- REXULTI$488
- EXXUA$282
- INGREZZA$246
- Karbinal$144
- ABILIFY ASIMTUFII$122
How this compares
$283,987 in reported general payments places this provider in the 95th percentile of 49 adolescent medicine providers in Virginia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SuboxoneBuprenorphine Hcl/Naloxone Hcl | 20 | $15,881 |
| VyvanseLisdexamfetamine Dimesylate | 26 | $10,053 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 110 | $9,524 |
| TrintellixVortioxetine Hydrobromide | 14 | $8,868 |
| Jornay PmMethylphenidate Hcl | 15 | $6,829 |
| Adzenys Xr-OdtAmphetamine | 14 | $6,558 |
| Lisdexamfetamine Dimesylate | 24 | $4,447 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 73 | $2,816 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 66 | $1,278 |
| Methylphenidate Hcl | 19 | $497 |
| Lithium Carbonate ErLithium Carbonate | 11 | $223 |
| Clonazepam | 37 | $204 |
| Escitalopram Oxalate | 30 | $183 |
| Zolpidem Tartrate | 15 | $180 |
| Alprazolam | 28 | $146 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse, Trintellix | $468 | $18,92140 claims |
| Indivior Inc.Suboxone | $108 | $15,88120 claims |
| Ironshore Pharmaceuticals Inc.Jornay Pm | $140,973 | $6,82915 claims |
| Neos Therapeutics, LPAdzenys Xr-Odt | $77,366 | $6,55814 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 49 adolescent medicine providers in Virginia.
Other adolescent medicine in Midlothian
- John ZacharyMidlothian$320K
- Michele BurgetMidlothian$152K
- Judith McGheeMidlothian$15
- Robert ShayneChester$165K
- Kerri SteeleChester$164K
- Mark PolanshekChester$164K
- Kevin CampbellChester$164K
- Alok RustogiPotomac Falls$9K
- Peter HeymanRichmond$3K
- George RoweRichmond$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.